GT Biopharma
GTBP | NASDAQ
$3.54
-$0.18 (-4.84%)
At close: Nov 16, 2026, 4:00 PM ET
$3.61
+$0.07 (+1.98%)
After-hours:
Nov 16, 2026, 6:41 PM ET
GT Biopharma Company Profile
Company profile explainedCompany Profile
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.
Key Executives
| Name | Position |
|---|---|
| Michael Martin Breen | President, CEO & Executive Chairman |
| Alan Louis Urban | Chief Financial Officer & Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 20, 2026 | EFFECT | Filing |
| Oct 20, 2026 | 424B3 | Filing |
| Oct 13, 2026 | DEF 14A | Filing |
| Oct 09, 2026 | S-1 | Filing |
| Oct 02, 2026 | PRE 14A | Filing |
| Sep 29, 2026 | D | Filing |
| Sep 25, 2026 | 8-K | Current Report |
| Sep 21, 2026 | 8-K | Current Report |
| Sep 15, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 15, 2026 | 8-K | Current Report |
GT Biopharma
| Country | United States |
| IPO Date | Mar 27, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Michael Martin Breen |
Contact Details
315 Montgomery Street San Francisco,
California 94104 United States
Stock Details
| Ticker Symbol | GTBP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000109657 |
| CUSIP Number | 36254L407 |
| ISIN Number | US36254L4077 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove GTBP